Orthocell has been featured in The Market Herald, following the announcement of a newly granted U.S. divisional patent for CelGro.
Read the article HERE.
Orthocell’s stock soars following FDA 510(k) clearance of regenerative collagen medical device
BioWorld has reported on Orthocell’s rising share price, following the U.S. approval for our collagen medical device for dental guided bone and soft tissue regeneration applications.
UWA invention to speed up healing in dental patients
Orthocell’s Striate+â„¢ has been featured in Bite Magazine, highlighting its effectiveness for dental bone defect repair and tissue augmentation around dental implants.
Australia’s TGA approves Orthocell’s Celgro™ regenerative collagen medical device
Orthocell CEO Paul Anderson spoke to BioWorld, following marketing clearance from Australia’s Therapeutic Goods Administration (TGA) for our Celgroâ„¢ collagen medical device for dental guided bone and soft tissue regeneration applications.Â
Medical miracle brings limbs back to life
The incredible story of Adrian Walsh, featuring Orthocell’s CelGroâ„¢ nerve treatment, has been featured in the Weekend Australian.
HCP Webinar | Latest Developments in the Biological Treatment of Cartilage – Professor Martin Sullivan
Professor Martin Sullivan Foot and Ankle Surgeon at St. Vincent’s Clinic & North Shore Private Hospital in Sydney presents ‘An Australian Perspective on the Management of Large Cartilage Defects in the Ankle Over 25 Years’
Video | Proactive Investors Interview – September 2020
Orthocell CEO and Managing Director Paul Anderson spoke with Andrew Scott from Proactive Investors about the company being in an exciting regulatory phase, having validated its technologies in the clinic and defining pathways to market through the US FDA process.
Australia’s Orthocell submits 510(k) for Celgro™ regenerative collagen medical device
Orthocell has been featured in BioWorld, following the submission of a 510(k) application to the U.S. FDA for our Celgroâ„¢ collagen medical device for dental guided bone and soft tissue regeneration applications.
Orthocell looks to enter US market following positive CelGroâ„¢ study results
Small Caps has featured Orthocell’s plans to enter the US market following the success of our Celgroâ„¢ dental implant study.Â
Orthocell – The Next Big Winner In The Regenerative Sector
Greg Tolpigin has published positive commentary about the future of Orthocell, and the potential for our CelGroâ„¢ product in this article on Sharecafe.Â